JP2013511507A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511507A5
JP2013511507A5 JP2012539433A JP2012539433A JP2013511507A5 JP 2013511507 A5 JP2013511507 A5 JP 2013511507A5 JP 2012539433 A JP2012539433 A JP 2012539433A JP 2012539433 A JP2012539433 A JP 2012539433A JP 2013511507 A5 JP2013511507 A5 JP 2013511507A5
Authority
JP
Japan
Prior art keywords
palonosetron
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539433A
Other languages
English (en)
Japanese (ja)
Other versions
JP5890780B2 (ja
JP2013511507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/003106 external-priority patent/WO2011061622A1/en
Publication of JP2013511507A publication Critical patent/JP2013511507A/ja
Publication of JP2013511507A5 publication Critical patent/JP2013511507A5/ja
Application granted granted Critical
Publication of JP5890780B2 publication Critical patent/JP5890780B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539433A 2009-11-18 2010-11-18 中枢を介する悪心および嘔吐を治療するための組成物および方法 Active JP5890780B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US61/262,470 2009-11-18
US38270910P 2010-09-14 2010-09-14
US61/382,709 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en) 2009-11-18 2010-11-18 Compositions for treating centrally mediated nausea and vomiting

Publications (3)

Publication Number Publication Date
JP2013511507A JP2013511507A (ja) 2013-04-04
JP2013511507A5 true JP2013511507A5 (https=) 2014-01-09
JP5890780B2 JP5890780B2 (ja) 2016-03-22

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539433A Active JP5890780B2 (ja) 2009-11-18 2010-11-18 中枢を介する悪心および嘔吐を治療するための組成物および方法

Country Status (40)

Country Link
US (1) US12042494B2 (https=)
EP (3) EP2727590B1 (https=)
JP (1) JP5890780B2 (https=)
KR (1) KR101615108B1 (https=)
CN (6) CN106421793B (https=)
AP (1) AP3083A (https=)
AU (1) AU2010320598B2 (https=)
BR (1) BR112012011485B1 (https=)
CA (1) CA2778301C (https=)
CL (1) CL2012001276A1 (https=)
CO (1) CO6551693A2 (https=)
CR (1) CR20120216A (https=)
CU (1) CU24048B1 (https=)
CY (1) CY1118062T1 (https=)
DK (2) DK2361090T3 (https=)
DO (1) DOP2012000138A (https=)
EA (1) EA026815B1 (https=)
EC (1) ECSP12011907A (https=)
ES (4) ES2623503T3 (https=)
GE (1) GEP20156226B (https=)
GT (1) GT201200156A (https=)
HK (2) HK1214148A1 (https=)
HR (3) HRP20140759T1 (https=)
HU (1) HUE029677T2 (https=)
IL (1) IL219576A (https=)
LT (1) LT2722045T (https=)
MA (1) MA33810B1 (https=)
MX (1) MX2012005347A (https=)
MY (1) MY159393A (https=)
NI (1) NI201200090A (https=)
NZ (1) NZ599439A (https=)
PE (1) PE20121483A1 (https=)
PH (1) PH12012500887A1 (https=)
PL (3) PL2361090T3 (https=)
PT (2) PT2361090E (https=)
RS (2) RS55206B1 (https=)
SI (2) SI2361090T1 (https=)
SM (1) SMT201400112B (https=)
TN (1) TN2012000170A1 (https=)
WO (1) WO2011061622A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2013004766A1 (en) * 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
CN105412110B (zh) * 2011-10-18 2018-05-25 赫尔森保健股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
ES2824552T3 (es) 2015-03-04 2021-05-12 Vanda Pharmaceuticals Inc Método de tratamiento con tradipitant
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
EP3746078A4 (en) * 2018-02-02 2021-11-17 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) ORAL FORMULATIONS AND USES THEREOF
AU2021407138A1 (en) * 2020-12-25 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2025246530A1 (en) * 2024-05-30 2025-12-04 The Chinese University Of Hong Kong Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL166267B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
PT1035115E (pt) 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
MXPA03000366A (es) 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
JP4116436B2 (ja) 2000-12-14 2008-07-09 エフ.ホフマン−ラ ロシュ アーゲー 自己乳化脂質マトリックス(selm)
DE10393729T5 (de) 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007096763A2 (en) 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
KR101441459B1 (ko) 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
JP2011505873A (ja) * 2007-12-18 2011-03-03 シェーリング コーポレイション 抗igf1r療法に対する感受性のバイオマーカー
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente

Similar Documents

Publication Publication Date Title
JP2013511507A5 (https=)
TWI595873B (zh) 用於治療中樞誘發噁心及嘔吐之組成物及方法
JP5890780B2 (ja) 中枢を介する悪心および嘔吐を治療するための組成物および方法
CN103096881B (zh) 含有具有不愉快味道的药物的膜制剂
JP2009102342A5 (https=)
JP2009525343A5 (https=)
JP2011068653A5 (https=)
JP2005515966A5 (https=)
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
JP2012533565A5 (https=)
UA102885C2 (ru) Таблетка для орального введения, которая содержит тамсулозин и солифенацин
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP2009517411A5 (https=)
JP2018039810A5 (https=)
ES2706994T3 (es) Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona
JP2012041314A5 (https=)
ZA202405485B (en) Solid oral dosage forms of rabeprazole
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
JP2014511850A5 (https=)
JP2015515971A5 (https=)
JP2017515858A5 (https=)
RU2017136693A (ru) Способы поддержания, лечения или улучшения когнитивной функции
CN101143143A (zh) 一种治疗胃食管反流疾病与功能性消化不良的药物
HK1228787B (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1171391A (en) Compositions and methods for treating centrally mediated nausea and vomiting